Palisade Bio (NASDAQ:PALI) Shares Scheduled to Reverse Split on Monday, April 8th

Palisade Bio, Inc. (NASDAQ:PALI) shares are going to reverse split on Monday, April 8th. The 1-15 reverse split was announced on Monday, April 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 8th.

Palisade Bio Stock Down 1.4 %

NASDAQ:PALI traded down $0.01 during trading hours on Thursday, reaching $0.38. The company had a trading volume of 152,423 shares, compared to its average volume of 2,530,181. Palisade Bio has a twelve month low of $0.36 and a twelve month high of $2.44. The firm has a market cap of $3.56 million, a price-to-earnings ratio of -0.21 and a beta of 1.33. The business’s 50-day simple moving average is $0.44 and its two-hundred day simple moving average is $0.52.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Palisade Bio in the fourth quarter valued at approximately $31,000. Vanguard Group Inc. lifted its holdings in shares of Palisade Bio by 91.3% in the 3rd quarter. Vanguard Group Inc. now owns 68,054 shares of the company’s stock worth $40,000 after purchasing an additional 32,485 shares in the last quarter. State Street Corp acquired a new stake in Palisade Bio in the 2nd quarter valued at $38,000. Geode Capital Management LLC acquired a new stake in Palisade Bio in the 2nd quarter valued at $72,000. Finally, Renaissance Technologies LLC increased its stake in Palisade Bio by 1,396.0% during the 3rd quarter. Renaissance Technologies LLC now owns 512,070 shares of the company’s stock valued at $51,000 after purchasing an additional 477,840 shares in the last quarter. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.